Reported Sunday, Amgen's Repatha Cuts First Major Cardiovascular Event Risk By 29% In High-Risk Diabetes Patients In VESALIUS-CV Subgroup Analysis
Reported Sunday, Amgen's Repatha Cuts First Major Cardiovascular Event Risk By 29% In High-Risk Diabetes Patients In VESALIUS-CV Subgroup Analysis
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day